Spoken Alpha
BioXcel Therapeutics, Inc.
BioXcel Therapeutics develops medicines for neuroscience and immuno-oncology using an AI platform to identify new therapeutic uses for existing drugs. The company's lead product, IGALMI® (dexmedetomidine sublingual film), is FDA-approved for acute agitation in schizophrenia and bipolar disorder, with ongoing trials for at-home use and Alzheimer's disease.
BioXcel Therapeutics, Inc is a Healthcare company operating in Drug Manufacturers - Specialty & Generic with a $2.3M market cap.
BTAI beat consensus EPS by 0.0% in Q2 FY2026, reported Aug 12, 2026.
14 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-08-30.
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for BTAI.
$ curl https://api.spokenalpha.com/v1/companies/BTAIFAQ
Spoken Alpha indexes BTAI's earnings call transcripts at https://spokenalpha.com/companies/BTAI. Each call links to attributed speakers and parsed analyst Q&A. BioXcel Therapeutics, Inc.'s own investor relations page is at https://ir.bioxceltherapeutics.com/.
BioXcel Therapeutics, Inc. (BTAI) held its most recent earnings call on 2024-11-14, covering fiscal Q3 2024.
BioXcel Therapeutics, Inc. (BTAI) operates in the Healthcare sector (Drug Manufacturers - Specialty & Generic industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-12 | $-0.49 | $-0.51 | +3.9% | $182.0K | — | — | EODHD |
| Q1 FY2026 | 2026-05-14 | $-0.54 | $-0.48 | -12.5% | $206.0K | — | — | EODHD |
| Q4 FY2025 | 2026-03-26 | $-1.03 | $-0.64 | -61.8% | $256.0K | — | — | EODHD |
| Q3 FY2025 | 2025-11-11 | $-2.16 | $-1.34 | -61.2% | $98.0K | — | — | EODHD |
| Q2 FY2025 | 2025-08-11 | $-2.45 | $-1.56 | -57.0% | $120.0K | — | — | EODHD |
| Q1 FY2025 | 2025-05-11 | $-1.50 | $-3.04 | +50.7% | $168.0K | — | — | EODHD |
| Q4 FY2024 | 2025-03-09 | $-3.56 | $-5.14 | +30.7% | $366.0K | — | — | EODHD |
| Q3 FY2024 | 2024-11-13 | $-5.12 | $-7.68 | +33.3% | $214.0K | — | — | EODHD |
| Q2 FY2024 | 2024-08-05 | $-3.36 | $-10.99 | +69.4% | $1.1M | — | — | EODHD |
| Q1 FY2024 | 2024-05-08 | $-0.87 | $-0.70 | -24.3% | $582.0K | — | — | EODHD |
| Q4 FY2023 | 2024-03-11 | $-12.16 | $-12.72 | +4.4% | $376.0K | — | — | EODHD |
| Q3 FY2023 | 2023-11-13 | $-25.32 | $-20.00 | -26.6% | $341.0K | — | — | EODHD |
| Q2 FY2023 | 2023-08-13 | $-29.28 | $-27.68 | -5.8% | $457.0K | — | — | EODHD |
| Q1 FY2023 | 2023-05-07 | $-1.84 | $-1.62 | -13.6% | $206.0K | — | — | EODHD |
| Q4 FY2022 | 2023-03-08 | $-31.20 | $-22.61 | -38.0% | $238.0K | — | — | EODHD |
| Q3 FY2022 | 2022-11-09 | $-23.84 | $-20.84 | -14.4% | $137.0K | — | — | EODHD |
| Q2 FY2022 | 2022-08-08 | $-21.60 | $-18.89 | -14.3% | $0 | — | — | EODHD |
| Q1 FY2022 | 2022-05-08 | $-1.12 | $-1.15 | +2.6% | $0 | — | — | EODHD |
| Q4 FY2021 | 2022-03-09 | $-14.88 | $-16.21 | +8.2% | $0 | — | — | EODHD |
| Q3 FY2021 | 2021-11-09 | $-15.36 | $-16.56 | +7.2% | $14.9K | — | — | EODHD |
Source: EODHD. BTAI reported actuals as published; sparse fields render as —.